

Amerisourcebergen Corporation Logo

Bergen Brunswig Named Recipient Of Communicator Award

April 24, 2001

Orange, CA - April 24, 2001 - Bergen Brunswig Corporation (NYSE: BBC), has received the prestigious Crystal Award of Excellence in the 2001 Print Media Competition for its Code of Conduct project titled "Legacy of Integrity."

The Communicator Awards is an independent, national awards organization founded by communications professionals to recognize outstanding work in the communications field. Over 3,300 international entries were judged by communications professionals who look for individuals and companies whose talent exceeds a high standard of excellence and whose work serves as a benchmark for the industry.

The "Legacy of Integrity" is a program designed to communicate to associates the Company's requirements for their ethical and moral behavior. Completion of the "Legacy of Integrity" course is compulsory for all Bergen Brunswig associates.

Bergen Brunswig's Senior Executive Vice President and Chief Legal and Compliance Officer Milan Sawdei stated, "This award shows our commitment to successfully communicate our values and business standards to our associates. Our goals at Bergen Brunswig are accompanied by a firm base of ethical business practices and conduct."

Bergen Brunswig Corporation, headquartered in Orange County, California, is a leading supplier of pharmaceuticals and specialty healthcare products, as well as information management solutions and consulting services. Bergen's customers include the nation's healthcare providers (hospitals, nursing homes and physicians), drug stores, manufacturers and patients. Through its subsidiaries, Bergen provides product distribution; logistics; pharmacy management programs; and Internet fulfillment strategies designed to reduce costs and improve patient outcomes across the entire healthcare spectrum.

Except for historical information, all other information set forth in this press release, such as earnings forecasts and earnings rate projections, consists of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking statements" are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those projected or implied. Such statements may be identified by the use of forward-looking language such as "may," "will," "should," "expect," "anticipate," "estimate," "believe," "think," "continue" or the negatives or other variations thereof or other similar terminology. Such risks and uncertainties include the risks described in exhibit 99(a) to the Company's Annual Report on Form 10-K for the year ended September 30, 2000 and in other reports and exhibits filed with the Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, the costs and difficulties related to the integration of acquired businesses, the loss or disruption of one or more key customer or supplier relationships, changes in the distribution outsourcing pattern for pharmaceutical products and/or services, the ability to obtain general financing or financing rates that would be compatible with the Company's business operations, and the costs and other effects of governmental regulation and legal and administrative proceedings. The Company assumes no obligation to update the information in the release.

Bergen Brunswig press releases are available on the company's website at www.bergenbrunswig.com.